News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Adolor Corporation Partner Glaxo Group Ltd. Plans Added Phase III Study on Its Bowel Drug
March 13, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
March 12 (Reuters) - Adolor Corp. (ADLR.O: Quote, Profile , Research) said on Monday that its partner Glaxo Group Ltd. has planned an additional Phase III study to evaluate the efficacy and safety of the experimental bowel treatment drug, Entereg.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
December 11, 2025
·
1 min read
·
Annalee Armstrong
Obesity
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges
December 11, 2025
·
3 min read
·
Annalee Armstrong
Breast cancer
Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer
December 11, 2025
·
2 min read
·
Tristan Manalac
Breast cancer
Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer
December 11, 2025
·
2 min read
·
Tristan Manalac